ESPE Abstracts (2022) 95 RFC9.1

ESPE2022 Rapid Free Communications Pituitary, Neuroendocrinology and Puberty (6 abstracts)

The Incidence of Congenital Combined Pituitary Hormone Deficiency in Denmark - a national observational study

Louise Kjersgaard Jakobsen 1,2 , Rikke Beck Jensen 3,4 , Niels Holtum Birkebæk 5,6 , Dorte Hansen 1,7 , Ann-Margrethe Rønholt Christensen 8 & Henrik Thybo Christesen 1,2,7


1Hans Christian Andersen Children´s Hospital, Odense University Hospital, Odense, Denmark; 2OPEN, Open Patient data Explorative Network, Odense University Hospital, Odense, Denmark; 3Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; 4Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; 5Department of Pediatrics and Adolescent Medicine and Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark; 6Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; 7Department of Clinical Research, University of Southern Denmark, Odense, Denmark; 8Department of Pediatrics, Aalborg University Hospital, Aalborg, Denmark


Background: Congenital combined pituitary hormone deficiency (cCPHD) is the loss of ≥2 pituitary hormones caused by genetic or prenatal factors.

Methods: For the period 1996–2020, patients with cCPHD were identified from the Danish National Patient Registry and the registries at the four Danish hospitals approved for the management of cCPHD. Retrospective hospital file reviews were performed to validate the diagnosis by uniform criteria. Incidence estimations were performed using background population data.

Findings: We identified a national cCPHD cohort of 127 cCPHD patients, whereof 115 patients were born in Denmark and diagnosed before age 18 years. Eighty-eight (69•3%) were males. The median (range) age at cCPHD diagnosis was 5•9 (0•01–19•04) years. The national incidence (95% CI) of cCPHD diagnosed before age 18 years was 10•12 (7•60–13•47) per 100,000 births from 1996–2002, corresponding to an annual incidence rate of 5•62 (4•22–7•48) per million. The incidence was highest in the group of patients diagnosed aged 1–17 years; 7•75 (5•59–10•75) per 100,000 births, whereas the annual incidence rate was highest in patients diagnosed <1 year; 19•8 (13•9–28•4) per million births. The median (P25, p75) number of hormone deficiencies at cCPHD diagnosis was 3 (2•5; 4) in patients diagnosed aged <1 year vs. 2 (2; 2) in patients diagnosed aged 1–17 years; P<0•0001. Abnormal brain MRI findings were seen in 96•7% (29/30) diagnosed aged <1 year, decreasing to 85•2% (69/81) in the 1–17 years group.

Interpretation: cCPHD had the highest annual incidence rate and the most hormonal deficiencies in patients diagnosed before age 1 year. As late-onset cCPHD had the highest incidence, our study underscores the need for investigations for cCPHD throughout childhood and adolescence in children with isolated PHD.

Funding: Odense University Hospital Fund (j.no. A4599) and Dagmar Marshalls Fund (29/04/2021).

Volume 95

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

Authors